Pharofen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pharofen

Property Description
Active ingredient Diclofenac (as sodium or potassium salt)
Primary Forms Tablet, Capsule, Solution, Gel, Suppository
Pharmacological Class Non-steroidal anti-inflammatory drug (NSAID)
General Purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic compound (Phenylacetic acid derivative)

What Type of Medicine is Pharofen? Classification and Composition

Pharofen is a widely recognized brand name for a medicinal product whose active substance is Diclofenac, a potent compound classified as a Non-steroidal anti-inflammatory drug (NSAID). This compound is a synthetic drug that belongs to the phenylacetic acid derivative group, chemically distinct from many common analgesics. Its classification as an NSAID signifies that the drug's core action is related to inhibiting specific cyclooxygenase enzymes in the body. Diclofenac functions as a non-selective inhibitor of cyclooxygenase, a therapeutic profile recognized for its effectiveness across multiple inflammatory conditions. This confirms the medicine's role as a core pharmaceutical tool for reducing inflammation and addressing symptomatic discomfort.

Understanding Pharofen’s Available Forms and Delivery Systems

Pharofen is distinguished by its availability across multiple pharmaceutical preparations designed to suit various patient needs, ensuring its delivery is either systemic or localized. The medicine is commonly available in several dosage forms, including tablets and capsules for oral use—a highly common route of administration—and semi-solid preparations such as gels for topical skin application. Diclofenac is available in these different forms, which allows for either a systemic effect (affecting the whole body) or a targeted local effect (concentrated at a specific area). This versatility ensures the medicine can be applied precisely where it is needed.

The General Purpose of Pharofen: Relief from Pain and Inflammation

The general purpose of Pharofen is to provide broad symptomatic relief by addressing the interrelated issues of pain, inflammation, and fever. Due to its pharmacological action as an inhibitor of prostaglandin synthesis, the medicine is capable of delivering three key effects: analgesia (pain relief), an anti-inflammatory effect (reduction of swelling), and antipyresis (fever reduction). This combination of actions makes it a fundamental agent for managing acute discomfort, such as the initial pain and swelling following a minor musculoskeletal injury.

Regulatory References

  1. Diclofenac Information (NIH/NCBI)
  2. FDA Drug Label: Diclofenac Sodium Gel

What side effects are possible with Pharofen?

The safety characteristics and possible side effects of Pharofen (Diclofenac) are classified and documented according to official regulatory labeling, reflecting the standard safety profile of a Non-steroidal anti-inflammatory drug (NSAID).

Documented Adverse Reaction Scope

Adverse reactions are formally grouped by the body system affected and frequency, ranging from Common to Rare in regulatory summaries. Common effects often involve Gastrointestinal disorders, such as dyspepsia, nausea, abdominal pain, and diarrhea. Other frequently documented effects involve the Nervous system (headache and dizziness) and reversible increases in liver enzymes.

Serious Safety Risks

Official labeling specifically documents the potential for serious adverse reactions, which, while uncommon, are clinically significant. These include serious Gastrointestinal events, such as bleeding, ulceration, and perforation, which can occur without warning symptoms at any time during use. The profile also highlights the risk of serious Cardiovascular thrombotic events, including myocardial infarction and stroke.

Contextual and Population Safety Considerations

The risk for certain serious events is formally stated to be related to the duration of use and the dosage administered. Furthermore, the regulatory profile includes specific cautions for certain patient populations. Older adults are officially documented as being at a significantly higher risk for serious gastrointestinal adverse events. Use is generally contraindicated in patients with active gastrointestinal ulceration, severe uncontrolled heart failure, and during the third trimester of pregnancy, as defined in government prescribing information.

Overdose and Emergency Response

Pharofen Overdose and when to seek help

Overdose scope

Classification Detail (As stated in regulatory documents)
Documented overdose presentations Gastrointestinal upset (including nausea, vomiting, abdominal pain), Tinnitus (ringing in the ears), Drowsiness, and Dizziness.
Physiological systems affected Gastrointestinal tract (bleeding/ulceration), Central Nervous System (drowsiness, possible coma/seizures in severe cases), Renal System (acute kidney failure), and Cardiovascular System (hypotension/shock).
Dose-related or exposure-related factors The risk of adverse events, including those leading to overdose symptoms, may increase with higher doses and longer duration of use.
Population-specific overdose notes Elderly patients may be at increased risk of serious adverse effects following over-ingestion, specifically regarding gastrointestinal bleeding and renal impairment.
Emergency-response statements In case of overdose, immediately contact the local Poison Control Center or seek emergency medical help right away.
When immediate medical help is required Seek medical attention immediately if symptoms such as chest pain, shortness of breath, sudden weakness or numbness, slurred speech, bloody/black stools, or vomiting blood are observed.

Overdose classifications (high-level)

Classification Detail (As defined in official documents)
Severity classification Overdose is typically classified as mild but can progress to severe toxicity with large ingestions.
Regulatory basis Information is derived from official warnings concerning Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) mandated by agencies such as the FDA and EMA.
Overdose-context constraints Treatment for overdose is supportive and symptomatic; there is no specific antidote defined in regulatory labeling.

Resulting overdose structure

Official overdose statements:

  • The primary overdose manifestations involve the central nervous system and the gastrointestinal system.
  • Serious life-threatening outcomes can include acute renal failure, severe gastrointestinal bleeding, and cardiovascular collapse in massive ingestions.
  • Prompt medical intervention is required for all suspected or known overdoses to implement supportive care and monitoring.

Connection to the overall overdose profile (2–4 sentences): Official regulatory documents define the overdose profile by stating a range of presentations, from mild upset to serious systemic toxicity affecting the kidneys and the cardiovascular system. The immediate need to seek emergency medical help is driven by the potential for life-threatening, un-warned outcomes like internal bleeding or cardiac events, which necessitate immediate, expert symptomatic management.

Therapeutic Uses of Pharofen

What Pharofen Treats: Main Uses and Benefits

Pharofen is a medication commonly used to help with symptoms related to physical discomfort and inflammatory or irritative states associated with various conditions. This medication is generally used for symptomatic support across several therapeutic domains.

It is commonly used across conditions presenting with episodic or fluctuating manifestations, including symptomatic support for conditions such as Osteoarthritis, Rheumatoid arthritis, and Ankylosing Spondylitis, as well as in acute episodes like Gouty arthritis and painful menstrual periods (Primary Dysmenorrhea).

The medicine helps address symptom clusters that may become intense or disruptive, particularly pain, swelling, and stiffness. This provides support that helps ease the overall burden of symptoms and supports general well-being during symptomatic periods, which may assist with maintaining functional stability.

“The medication supports symptom management and contributes to improved comfort during periods of heightened discomfort.”

Quick Fact: Supports management of Joint Pain and Inflammation symptoms

Regulatory References

  1. NIH MedlinePlus overview on Diclofenac

Eligibility and Restrictions for Use

Official Eligibility Profile

This section defines the populations for whom use of Pharofen is officially contraindicated or restricted, as documented in government regulatory labeling. The rules govern who is eligible to use the medicine based on specific health status and demographics.


Populations Who Must Not Use (Contraindicated)

Category Description
Allergy/Hypersensitivity Patients with a history of allergic reactions (e.g., asthma, urticaria, or anaphylaxis) to this medicine, aspirin, or other NSAIDs (Nonsteroidal Anti-inflammatory Drugs).
Cardiac Surgery Use is strictly prohibited in the peri-operative period of Coronary Artery Bypass Graft (CABG) surgery.
Pregnancy Women who are 30 weeks pregnant or later due to the risk of fetal cardiovascular harm.
GI History Patients with a current or history of recurrent gastrointestinal bleeding or ulceration related to previous NSAID therapy.

Populations Requiring Restricted or Conditional Use

Category Description
Cardiovascular Risk Patients with known risk factors (e.g., hypertension, recent myocardial infarction) must use the medicine with caution, typically at the lowest effective dose for the shortest duration.
Renal/Hepatic Impairment Patients with advanced renal or severe hepatic disease must generally avoid use unless benefits are carefully weighed. Renal function must be monitored.
Early Pregnancy Use between 20 and 30 weeks of pregnancy is restricted to the lowest effective dose for the shortest duration, with monitoring for fetal renal dysfunction.

Official regulatory documents define these exclusions and restrictions to ensure that use is limited to eligible populations and avoided by those at high risk of serious adverse health events.

What should I know about interactions with other medicines?

Pharofen (Diclofenac) exhibits a documented interaction profile primarily involving combined risk factors and alteration of drug clearance, as detailed in regulatory labeling. Co-administration with other systemic NSAIDs, including COX-2 selective inhibitors, is not generally recommended due to the officially confirmed additive risk of serious gastrointestinal bleeding and ulceration.

The medicine demonstrates several pharmacokinetic interactions. For example, co-use with strong CYP2C9 inhibitors like Voriconazole is documented to increase the systemic exposure of Diclofenac. Conversely, Pharofen can increase the plasma concentration of co-administered drugs such as Lithium, Digoxin, and Methotrexate by inhibiting their renal clearance.

Pharmacodynamic interactions include a heightened risk of serious bleeding when Pharofen is combined with Anticoagulants (Warfarin), Anti-platelet agents, SSRIs, or Systemic Corticosteroids. Furthermore, Pharofen may diminish the therapeutic effect of several Antihypertensive Agents, including ACE Inhibitors and Diuretics.

The regulatory profile also notes that specific oral formulations should not be taken with food as this may reduce their effectiveness. Finally, the elderly patient population is officially noted as having a heightened vulnerability to the consequences of GI and renal-related interactions.

Mechanism of Action

Core Mechanism: Cyclooxygenase ( COX) Enzyme Inhibition

The primary action of Pharofen (Diclofenac) is the non-selective, competitive inhibition of the Cyclooxygenase enzymes ( COX-1 and COX-2). This mechanism prevents the COX enzymes from converting arachidonic acid into prostaglandins and related eicosanoid mediators. This initial molecular step serves to modulate downstream inflammatory and pyretic responses in the body.

Modulating Peripheral Pain Signaling

The subsequent reduction in prostaglandin E2 ( PGE2) concentration at the tissue level dampens the sensitization of peripheral nociceptors (pain-sensing nerve endings). This mechanism results in an increase in the local nociceptor activation threshold by reducing the molecular factors that facilitate peripheral sensitization. This reduces the frequency of afferent signaling transmission.

Adjusting Central Thermoregulation

Pharofen’s mechanism also acts centrally by reducing PGE2 production within the hypothalamus, the brain region that controls the body's set temperature. This action results in the resetting of the elevated thermoregulatory set point, a central physiological change that facilitates the adjustment of core body temperature.

Dosage and Administration Information

How to Use Pharofen

Pharofen, which contains Diclofenac, is administered according to established usage principles to ensure consistent application in clinical practice. The choice of administration method is based on the therapeutic context, leading to either a systemic effect (affecting the whole body) or a localized effect.


Official Administration Routes and Forms

Pharofen is available across several administration routes, including oral (using immediate-release tablets, delayed-release tablets, extended-release capsules, or powder for solution), topical (gels and solutions), rectal (suppositories), and parenteral (intramuscular injection or intravenous infusion). The parenteral routes are generally reserved for acute situations and typically restricted to administration for not more than two days.


Standard Dosing and Frequency

Standard adult systemic dose ranges are 75 mg to 150 mg daily, with a general maximum daily dose of 150 mg when taken orally. Immediate-release forms are often taken in divided doses two or three times daily, while extended-release formulations are typically dosed once per day. Certain oral forms, such as the powder for solution, are specifically instructed to be taken on an empty stomach with a small amount of water to ensure proper intake.


Administration Requirements and Duration

Administration requires adherence to specific conditions: extended-release tablets must be swallowed whole and should not be crushed or chewed, as this alters the intended drug release pattern. The fundamental guiding principle for all systemic use is to utilize the lowest effective dose for the shortest duration necessary to address the acute or chronic need. Dosage adjustments, typically toward the lowest effective dose, are indicated for use in specific populations, including older adults and patients with known hepatic or renal impairment.

Recent Clinical Evidence

The research base for Pharofen (Diclofenac) includes Randomized Controlled Trials (RCTs) and Systematic Reviews utilized across its main approved indications. This research is essential for understanding the medicine’s clinical evaluation as described in authoritative sources.

Research for Osteoarthritis (OA) was conducted in adult and older populations focusing on the knee and hand joints. Studies examined outcomes related to physical discomfort and daily functioning or activity level. Findings described patterns of measured changes in patient-reported scores when compared to placebo or other medicines, with both oral and topical formulations being evaluated.

For Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS), research primarily utilized oral formulations in adults. Studies explored outcomes related to inflammatory states, monitoring joint tenderness, swelling, and changes in mobility capacity. Research described short-term measured changes in pain and stiffness scores, which contributes to the understanding of symptomatic patterns in these chronic conditions.

In the context of Acute Pain and Injuries, research, often involving single-dose RCTs, explored rapid, episodic or acute changes associated with conditions like Primary Dysmenorrhea and musculoskeletal injuries. Findings described measurement differences in pain intensity within the initial hours post-dose when compared to placebo.

The evidence base is characterized by limited long-term data. Follow-up durations were typically short to intermediate, meaning the persistence of observed symptomatic changes is not fully established over many years of potential use. Furthermore, research for certain special populations remains insufficient, particularly for pediatric populations and for certain complex subgroups defined by comorbidities.

Frequently Asked Questions (FAQ)

Common questions about Pharofen (FAQ)


Q: How quickly should I feel the effects of Pharofen?

A: The time it takes for an individual to notice the effects of this medicine can vary. This depends on the specific product formulation being used, such as an immediate-release tablet versus a delayed-release or topical application. Some formulations are designed by the manufacturer for faster absorption and a quicker expected onset of relief.


Q: How long does one dose of Pharofen typically last?

A: The active substance in Pharofen is cleared from the bloodstream relatively quickly, with an elimination half-life of approximately one to two hours. However, the overall therapeutic effect is established to last longer. Dosing frequency, which is determined by the specific product, is established to align with this clearance period.


Q: Does Pharofen make you drowsy or sleepy?

A: Official adverse reaction reports document that certain central nervous system effects, such as dizziness, headache, and somnolence (sleepiness), can occur when using this medicine. Due to these potential effects, it is advised to seek guidance before engaging in activities that require full mental alertness, such as driving or operating machinery.


Q: Can Pharofen affect birth control pills?

A: The official product information indicates that this medicine may interact with certain types of oral contraceptives, particularly those containing drospirenone, potentially increasing the risk of high potassium levels. Individuals taking birth control are encouraged to consult their healthcare provider to check for any potential conflicts with their specific contraceptive formulation.


Q: Is Pharofen safe for women who are breastfeeding?

A: Regulatory information indicates that the active ingredient in Pharofen does pass into breast milk, although typically in small amounts. While some sources indicate the use may be generally acceptable, official warnings and safety considerations apply, particularly when nursing a newborn or premature infant.


Q: What is the maximum number of days I can take Pharofen in a row?

A: The guiding principle for using this medicine is always to utilize the lowest effective dose for the shortest duration necessary. For certain over-the-counter (OTC) topical forms, official labeling specifies a limit of 21 consecutive days of use, which is the established limit for self-treatment as per the product's regulatory labeling.


Q: Are there long-term side effects associated with taking Pharofen regularly?

A: Yes, regulatory authorities issue official warnings that the risk of serious side effects is directly related to the duration of use and the dosage. These risks include potentially serious gastrointestinal events (like bleeding and ulcers) and cardiovascular thrombotic events (like heart attack and stroke), which may increase with prolonged use.


Q: Is Pharofen known to be addictive?

A: The active ingredient in Pharofen is classified as a Non-steroidal Anti-inflammatory Drug (NSAID). According to regulatory and controlled substance classification, it is not listed as having potential for abuse or dependence.


Q: Can children take Pharofen?

A: The safety and effectiveness of many systemic formulations of Pharofen have generally not been established for use in children, or 'pediatric patients.' For this reason, its use in this population is often restricted or not specifically recommended in the product's official prescribing information.


Q: Is there a generic version of Pharofen available?

A: Yes, the active ingredient in Pharofen is Diclofenac, which is available in a variety of generic products. Generic forms containing Diclofenac are manufactured by many companies and are widely accessible in various pharmaceutical forms.


Q: Can Pharofen be split or crushed to make it easier to swallow?

A: Most specialized formulations, such as delayed-release and extended-release tablets, are officially instructed to be swallowed whole. Cutting or crushing these specific forms is officially not recommended, as this practice would compromise the designed drug release pattern and potentially increase the risk of adverse effects.


Q: Is it normal to feel a tingling sensation after taking Pharofen?

A: Paresthesia, which is defined as an abnormal skin sensation such as tingling, burning, or prickling, is a documented but very rare nervous system disorder associated with the use of the medicine. Any such unusual sensation should be reported to a healthcare professional for evaluation.


Q: How long does Pharofen stay in your system after you stop taking it?

A: The terminal half-life of the unchanged medicine is approximately one to two hours. The body’s systems are designed to eliminate the substance through metabolism and excretion via urine and bile.


Q: Does Pharofen affect liver or kidney function?

A: Yes, official warnings are issued regarding the potential for both liver and kidney effects. Reversible increases in liver enzymes are a common side effect. The drug is associated with a risk of renal (kidney) toxicity and is generally contraindicated in patients with advanced renal or severe hepatic disease.


Q: Does Pharofen cause weight gain or loss?

A: Weight changes are not listed as a common side effect in the product's official labeling. However, fluid retention and peripheral edema (swelling, usually of the ankles or feet) are documented adverse effects, which may cause temporary fluid fluctuation.


Q: Why does Pharofen come in different strengths?

A: The medicine is manufactured in various strengths and specific formulations to enable healthcare providers to tailor the treatment to each patient's specific condition and need. This allows for adherence to the safety principle of prescribing the lowest effective dose possible.


Q: Are there any reported cases of Pharofen causing mood changes?

A: Yes, rare cases of psychiatric disorders have been documented in official regulatory reports. These can include effects such as depression, insomnia (inability to sleep), irritability, and psychotic disorders.


Q: Is it okay to take Pharofen before driving or operating machinery?

A: Official warnings note that the medicine may impair performance of skilled tasks. This is due to the possibility of side effects like dizziness, fatigue, or visual disturbances. Individuals should exercise care when engaging in activities requiring full concentration.


Q: Is Pharofen used for migraines?

A: Yes, certain specific formulations of the active ingredient (such as the powder for oral solution, Diclofenac Potassium) have been officially approved by regulatory bodies for the acute treatment of migraine attacks. However, this may not apply to all available forms of the medicine.


Q: Do you need a prescription to get Pharofen?

A: This varies by country and formulation. Most systemic forms (tablets, capsules) require a prescription from a licensed healthcare professional. However, certain low-strength topical forms, such as gels or solutions, have been reclassified and approved for over-the-counter (OTC) purchase in many regions.


Q: Can Pharofen mask symptoms of a more serious illness?

A: Official warnings caution that, due to its ability to reduce inflammation and fever, the medicine may mask the common signs and symptoms of an underlying infection. This characteristic requires vigilance for any signs of an underlying infection.


Q: Does the time of day matter when taking Pharofen?

A: While there are no overall time-of-day restrictions for all forms, administration instructions for specific products are important. For instance, certain immediate-release products are taken in divided doses, and one powder-for-solution form is specifically instructed to be taken on an empty stomach for proper absorption.


Q: Does Pharofen affect fertility?

A: Official product information notes that NSAIDs, including the active ingredient in Pharofen, are associated with a potential for reversible infertility in women. Official information suggests that consideration should be given to withdrawing the medicine in women experiencing difficulties conceiving.


Q: Is Pharofen the same as or very similar to Ibuprofen?

A: Pharofen contains the active ingredient Diclofenac. Both Diclofenac and Ibuprofen belong to the same pharmacological class, known as Non-steroidal Anti-inflammatory Drugs (NSAIDs). They share the same core mechanism of action, which is the inhibition of cyclooxygenase enzymes in the body.

How should Pharofen be stored and disposed of?

Official Storage and Disposal Instructions

Pharofen must be stored according to regulatory requirements to ensure its stability and effectiveness. The tablets are required to be kept at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F). Storage excursions are permitted up to 30 C.

The medication must be maintained in its tightly closed, original container and requires protection from moisture and light. A crucial safety requirement is to keep the product out of the reach of children.

For disposal, unused or expired Pharofen should be discarded according to local regulations, typically by utilizing a drug take-back program. The product must not be flushed down the toilet or released into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pharofen found in:

A-Z Index: